Morningstar sees Australia's Cochlear shares as slightly overvalued

Cochlear

18/12/2025 19:59

** Morningstar analysts see shares of Australia's Cochlear COH.AX as slightly overvalued as market extrapolates high cochlear unit sales

** Investment research firm expects revenue growth for hearing implant maker to moderate as average selling prices decline, given mix shift to lower-price emerging markets

** Says demand for Cochlear's sound processor upgrades softening with patients delaying upgrades due to cost-of-living pressures and satisfaction with older sound processors

** Notes next-largest competitor, Med- El, is also winning market share with its new sound processor offering, Sonnet 3

** Average rating of 15 analysts is "hold"; their median PT is A$299.77 – according to data compiled by LSEG

** Stock down nearly 11% YTD

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))